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DOI 10.1016/j.ccr.2010.01.022SUMMARYTranscriptional profiling of two isogenic models of transformation identifies a gene signature linking cancer
with inflammatory andmetabolic diseases. In accord with this common transcriptional program, many drugs
used for treatment of diabetes and cardiovascular diseases inhibit transformation and tumor growth.
Unexpectedly, lipid metabolism genes are important for transformation and are upregulated in cancer
tissues. As in atherosclerosis, oxidized LDL and its receptor OLR1 activate the inflammatory pathway
through NF-kB, leading to transformation. OLR1 is important for maintaining the transformed state in devel-
opmentally diverse cancer cell lines and for tumor growth, suggesting a molecular connection between
cancer and atherosclerosis. We suggest that the interplay between this common transcriptional program
and cell-type-specific factors gives rise to phenotypically disparate human diseases.INTRODUCTION
Clinical and epidemiological studies have linked cancer and other
chronic medical conditions. For example, patients diagnosed
with metabolic syndrome, inflammatory diseases, and autoim-
mune conditions show increased incidence and aggressiveness
of tumor formation (Giovannucci, 2007; Mantovani et al., 2008;
Pischon et al., 2008). Conversely, diabetics treated with metfor-
min to lower insulin levels have reduced levels of cancer in
comparison to untreated individuals (Hsu et al., 2007; Larsson
et al., 2007). Smoking is linked not only to lung cancer, but also
to cardiovascular and other diseases. In general, the molecular
bases of these links among diseases are poorly understood.Significance
Although there are epidemiological and clinical connections b
these connections are not well understood. mRNA expression
identifies a transcriptional signature and underlying gene reg
addition, it reveals the heretofore unappreciated importance
connection of cancer to atherosclerosis. These observations le
states are nevertheless linked through a common transcription
348 Cancer Cell 17, 348–361, April 13, 2010 ª2010 Elsevier Inc.Inflammation is commonly associated with cancer formation
and progression, and it is estimated that 15%–20% of all cancer
related deaths can be attributed to inflammation and underlying
infections (Mantovani et al., 2008). Inflammatory molecules are
elevated in many forms of cancer, and they provide growth
signals that promote the proliferation of malignant cells (Balkwill
and Mantovani, 2001; Karin, 2006; De Marzo et al., 2007; Naugler
and Karin, 2008; Pierce et al., 2009). Constitutively active NF-kB,
the key transcription factor that mediates the inflammatory
response, occurs in many types of cancer, and mouse models
provide evidence for a causative role of NF-kB in malignant
conversion and progression (Luedde et al., 2007; Naugler and
Karin, 2008; Sakurai et al., 2008).etween cancer and other diseases, the molecular bases of
profiling in two isogenic models of cellular transformation
ulatory networks that underlie diverse human diseases. In
of lipid metabolism to cellular transformation as well as the
ad to the view that a variety of phenotypically diverse disease
al program involving inflammatory and metabolic pathways.
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diabetes, high cholesterol, and atherosclerosis, which are com-
ponents of a disease state known as metabolic syndrome.
Mechanistically, the link between metabolic diseases and
cancer is less understood than the connection to inflammation.
However, a pathway consisting of AMP-activated protein kinase,
an energy sensor (Hardie, 2008), Akt, and PI3 kinase plays a
critical role in diabetes and other metabolic diseases, and
AMPK activation requires LKB1, a protein kinase that is a tumor
suppressor associated with Peutz-Jeghers syndrome (Shaw
et al., 2004; Shaw et al., 2005). In addition, fatty acid synthase
also plays an important role in cancer pathogenesis, and inhibi-
tors against this enzyme are being tested as anti-cancer drugs
(Kuhajda, 2006; Menendez and Lupu, 2007).
Transcriptional profiling has been a common way to identify
genes and signaling pathways important for carcinogenesis.
However, the various approaches have limitations with regard
to identifying genes relevant to cancer from those affected for
unrelated reasons. Clinical samples derive from a mixed pool
of patients with different clinical characteristics and different
cancer subtypes. Additionally, transcriptional profiles of primary
tumor samples are often not compared with normal matched
samples from the same patient that may be unavailable. Even
when normal matched samples are available, they are usually
derived from cells next to the tumor and may be affected by
the tumor microenvironment and/or may have some of the
genetic alterations as the tumor. Studies utilizing cell lines rarely
involve isogenically matched normal and transformed cell lines,
and we are unaware of a time-course analysis of the cellular
transformation process. The current study uses a different
approach to identify genes involved in cellular transformation
and carcinogenesis by performing transcriptional profiling in
two isogenic models of cellular transformation.
RESULTS
Identification of a Cancer Gene Signature
from Expression Profiling of Two Isogenic
Models of Cellular Transformation
To identify genes differentially regulated during the process of
cellular transformation, we used two isogenic cellular models
(Figure 1A) derived from different tissue types; i.e., for each
model, the nontransformed and transformed states are geneti-
cally identical. One model involves normal mammary epithelial
cells (MCF-10A) (Soule et al., 1990) containing ER-Src, a deriva-
tive of the Src kinase oncoprotein (v-Src) that is fused to the
ligand-binding domain of the estrogen receptor. Treatment of
such cells with tamoxifen rapidly induces Src, and morphological
transformation is observed within 24 to 36 hr (Hirsch et al., 2009;
Iliopoulos et al., 2009), thereby making it possible to kinetically
follow the transition between normal and transformed cells.
Transformation of these cells results in colony formation in soft
agar, foci formation rather than contact inhibition in monolayers,
formation of mammospheres in suspension, and tumors in nude
mice (Hirsch et al., 2009; Iliopoulos et al., 2009).
The other model consists of three isogenic cell lines derived
from primary fibroblasts in a serial manner (Hahn et al., 1999) (Fig-
ure 1A). The first is immortalized by overexpression of telomerase
(hTERT), and exhibits normal fibroblast morphology. The secondexpresses hTERT along with both large and small T antigens of
Simian virus 40, and it displays an altered morphology but is
not transformed. The third cell line expresses hTERT, T antigens,
and an oncogenic derivative of Ras (H-RasV12); it is morpholog-
ically transformed and has tumorigenic potential in soft agar and
nude mice. These two isogenic models of cellular transformation
differ with respect to cell type, oncogene, and mode of oncogenic
transition (time course or staged cell lines), and hence should
permit the identification of a gene signature common to the
process of cellular transformation.
Using microarrays capable of assaying most protein-coding
mRNAs, we performed transcriptional profiling of the transfor-
mation process in MCF-10A cells (eight time points from 1–36 hr
after tamoxifen treatment) and in the three fibroblast cell lines.
At a 1% false discovery rate by SAM analysis (Tusher et al.,
2001), we identified 1201 genes differentially expressed at any
time point in the ER-Src cells (Figure 1B; see Table S1 available
online) and 3208 genes (Figure 1C; Table S2) in any of the two-
way comparisons of the fibroblast cell lines. In the ER-Src model,
few genes were differentially expressed in the first time point
(1 hr), more than 100 genes 4 hr posttreatment, and more than
700 genes 36 hr postinduction. Interestingly, in the fibroblast
model, most changes in gene expression are due to T antigens,
not Ras, mirroring the morphology patterns but not transforma-
tion per se (Figure 1A), and suggesting that a viral oncogene
can deregulate multiple pathways to create a premalignant
phenotype.
The availability of transcriptional profiles for different isogenic
models of cellular transformation makes it possible to distinguish
between genes that play a relatively general role in transforma-
tion as opposed to those affected only by the specific experi-
mental model. We therefore analyzed the combined data sets
for differentially regulated genes that were either upregulated
or downregulated in both experimental models. We define a
gene signature of cellular transformation that contains 343 differ-
entially regulated genes of which 238 are upregulated and 105
are downregulated (Figure 1D; Table S3). This signature of differ-
entially expressed genes, hereafter termed the cancer gene
signature, will be the basis of bioinformatic approaches
described below.Identification of Transcription Factors Linked
to Cellular Transformation
The cancer gene signature is defined by coordinate regulation of
gene expression during the process of cellular transformation,
and such regulation must involve DNA-binding transcription
factors. To identify such transcription factors, we used a compu-
tational approach (Warner et al., 2008) that asks whether
DNA sequence motifs defined by comprehensive analysis of
protein-DNA binding specificity in vitro are statistically overrep-
resented in candidate gene sets. We considered 2 kb or 10 kb
(Table S4) of sequence flanking each side of the transcriptional
start site for genes included in the cancer gene signature as
well as subsets of genes comprising specific biofunction
categories. This analysis indicates that several families of tran-
scription factors play a role in transformation including Myc/
Max, IRF, Ets, Sox, Hox, Myb, KLF, GATA, and Pou (Figure 1E).
Interestingly, factors such as the SOX and Pou family membersCancer Cell 17, 348–361, April 13, 2010 ª2010 Elsevier Inc. 349
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Porath et al., 2008).
The Gene Signature of Cellular Transformation
Is Strongly Linked to Diverse Human Cancers
To validate our combined experimental system of cellular trans-
formation as a model of human cancer, we used two bioinfor-
matic approaches. First, we performed intensive literature
mining to correlate our gene signature with common 18 cancer
types. We found that 208/343 genes are correlated with at least
one cancer type (Table S5), with a range of 22-88 genes corre-
lated with each cancer type (Figure S1). K-means clustering
reveals 50 genes involved in most cancer types, including
STAT3, IL-1b, SOCS3, VEGF, HIF1a, and TGF-b1, which play
a significant role in inflammation. Second, we compared our
cancer gene signature with array-based transcriptional profiles
of specific cancer types. As shown in Figure 1F, the 343 common
gene set significantly overlaps inflammatory (breast [Lerebours
et al., 2008] and gastrointestinal [Ellmark et al., 2006]) and
metabolism-related (thyroid [Delys et al., 2007] and pancreatic
[Logsdon et al., 2003]) cancers (Table S6). Thus, the gene signa-
ture defined by our isogenic models of cellular transformation is
very strongly linked to diverse human cancers, thereby validating
these experimental systems as models of oncogenesis.
Linkage of the Cancer Gene Signature
to Metabolic Diseases, Including Obesity,
Diabetes, and Atherosclerosis
Using ingenuity pathway analysis, we identified three groups
of biofunctions and diseases that are significantly correlated
(p < 105) with the cancer gene signature (Table S7). The first
group includes cancer-related biofunctions such as cellular
growth and proliferation, cell cycle, and cell death. The second
group contains genes involved in inflammation and immune
system function, as well as genes linked to inflammatory and
gastrointestinal diseases. Many of these inflammatory genes
have been linked to cancer in the literature, in accord with the
multiple connections between cancer and inflammation. The
third group of biofunctions includes lipid metabolism, metabolic
disease, cardiovascular disease, and gastrointestinal disease.
Although certain aspects of metabolic disease have been linked
to cancer through the Akt pathway, the identification of multiple
genes involved in lipid metabolism was unexpected. For
example, OLR1, SREBP-1, SNAP23, and VAMP4 are well
described in studies of lipid metabolism, cholesterol biosyn-
thesis, and atherosclerosis, but have not been discussed in
terms of cancer.Figure 1. A 343-Gene Signature of Cellular Transformation
(A) Phase contrast images (scale bars represent 10 mm) of morphology of non
induction by tamoxifen (TAM) treatment. BJ fibroblasts have stable integration of
elements.
(B) Differentially expressed genes during MCF10A cell transformation at the indi
cutoffs.
(C) Differentially expressed genes in BJ fibroblasts were analyzed as two way com
4-fold) log cutoffs.
(D) The 343-gene signature of cellular transformation defined by the overlap of d
(E) Transcription factor families whose DNA-binding motifs are enriched in the 2 k
genes within the indicated biofunctions and diseases.
(F) Relationship between the 343 gene set and the indicated diseases. The overlAs an independent method to confirm the linkage between
cancer and metabolic diseases, we compared the cancer gene
signature identified here to microarray transcriptional profiling
studies from diseased individuals. There is significant overlap
between the cancer gene signature and expression signatures
found in obesity (Lee et al., 2005), atherosclerosis (Sluimer
et al., 2007; Skogsberg et al., 2008), and metabolic syndrome
(Chen et al., 2008) (Table S7). In addition, among a group of
54 genes, we observe a significant correlation between cancer
and various metabolic conditions (Figure 2A).
Gene Network Analysis Identifies Central Players
that Link Cellular Transformation to Metabolic Diseases
Although transcriptional profiling is useful for uncovering
common regulatory networks between disease states, it cannot
account for the contribution of protein-protein interactions, post-
translational modification, DNA-binding events, and subcellular
localization. To address this issue, we organized the set of differ-
entially expressed genes into networks with central nodes via
ingenuity pathways analysis. A three-way comparison between
networks derived from our two experimental data sets and
from a gene set describing metabolic syndrome reveals a high
overlap between the central nodes of cancer and metabolic
syndrome (Figure 2B). Specifically, we identified 24 common
central nodes, including inflammation-related nodes such as
IFN-g, IL-1b, IL-6, and NF-kB, suggesting that inflammatory
processes are important factors for both cancer and metabolic
diseases. In addition, insulin and low-density lipoprotein (LDL)
appear as central nodes in cancer gene networks, suggesting
the importance of protein and lipid metabolism in cellular
transformation.
To address the relationship between our cancer gene sig-
nature and human diseases that lack transcriptional profiling
data, we compiled gene sets based on literature-curated data,
and organized them into networks to identify central nodes
(Table S8). Interestingly, 10 out of 32 diseases were highly corre-
lated with cancer at the gene network level (Figures 2C and 2D
and Table S8). These diseases can be grouped as metabolic
disorders (obesity, type II diabetes, atherosclerosis, hypercho-
lesterolemia, and polycystic ovarian syndrome) and autoimmune
disorders (ulcerative colitis, Crohn’s disease, and SLE).
Genes Identified as Central Nodes Are Important
for Cellular Transformation
We validated the functional importance of these central nodes
for cellular transformation by a number of approaches: modula-
tion of function through drugs, modulation of expressiontransformed and transformed cells. MCF10A cells are transformed after Src
one (hTERT), two (hTERT, SV40E), or three (hTERT, SV40E, HRAS-V12) genetic
cated time points after TAM treatment using different (0.5-, 1-, and 2-fold) log
parisons in all combinations for the three cell types using different (0.5-, 1-, 2-,
ifferentially expressed genes in the two isogenic models.
b or 10 kb regions flanking the transcriptional start site of up- or downregulated
ap counts and p values are indicated.
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Figure 2. Linkage of the Cancer Gene Signature to Inflammatory and Metabolic Diseases
(A) Heat-map representation of the 54 common genes between cancer and subcategories of metabolic syndrome gene set.
(B) Common central nodes between gene networks derived from differentially expressed genes from MCF10A, BJ fibroblast, and metabolic syndrome gene sets.
Each sphere represents a central node of a gene network. The 24 common nodes are listed.
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Figure 3. Many Drugs Used to Treat Non-cancer Diseases Block
Cellular Transformation
(A) Percentage of transformed cells (morphology assay) observed by treating
TAM-induced MCF10 ER-Src cells with the indicated drugs.
(B) Soft agar colony assay of the effect of the indicated drugs on transformation.
(C) Tumor growth (mean ± SD) of ER-Src cells after four cycles of intraperito-
neal treatments with the indicated drugs.
Cancer Cell
Cancer Gene Signature Is Linked to Other Diseases(siRNA or overexpression), and modulation of cytokine levels
(antibodies or addition of exogenous cytokines). We chose
experimental conditions where the treatment did not significantly
affect the growth of nontransformed cells. Tamoxifen-treated or
non-tamoxifen-treated cells subjected to these perturbations
were examined for cellular transformation either by morphology
or by focus formation. Any perturbed node that decreased trans-(C) Comparison of genes and central nodes between the cancer gene signature a
cated). For each disease, the number of genes and nodes are indicated along with
of the overlap.
(D) Heat map representation of the relationship between common nodes of cel
indicated in red.formation of tamoxifen-treated cells or increased transformation
in non-tamoxifen-treated cells by at least 25% was considered
to have a contributing role to the transformation process
(summarized in Table S9). Importantly, all 23 nodes tested
affected cellular transformation when their function was altered.Drugs Designed for Treatment of Metabolic Diseases
Inhibit Cellular Transformation and Tumor Growth
The molecular similarities among the various diseases predicts
that drugs that designed or used for treatment of one disease
may also help treat other diseases or in this case cancer. We
therefore tested drugs that are used therapeutically for different
diseases for their ability to inhibit oncogenic transformation and
colony formation when plated in soft agar. Interestingly, 11 out of
13 drugs tested inhibit morphological transformation (Figure 3A),
and 12 out of 13 drugs tested suppress colony formation
(Figure 3B) to varying extents. The concentrations of the drugs
used in these experiments do not significantly affect cell growth
(Figure S2), indicating that their effects on transformation and
colony formation are not due to general cytotoxicity.
Because metformin, sulindac, tocilizumab, simvastatin, and
cerulenin show the strongest effects on cellular transformation
and tumorigenicity, we tested their ability to inhibit tumor growth
in nude mice. To mimic conditions when patients are diagnosed
with a tumor, we treated tumors that arose 10 days after injection
of transformed ER-Src cells. Drugs were delivered by five cycles
of intraperitoneal injections near the tumors every fifth day. Tumor
growth is completely suppressed by metformin and sulindac and
significantly delayed by cerulenin and simvastatin (Figure 3C).
The effect of metformin is much stronger than we observed
previously (Hirsch et al., 2009), presumably because drug
concentrations employed here are 8-fold higher and treatment
was for five cycles instead of three. Thus, drugs designed to
combat metabolic diseases can preferentially inhibit transformed
cells, and hence may be useful in treating some types of cancer.OLR1 and Other Lipid Metabolic Genes Are Important
for Cellular Transformation
As mentioned above, the cancer gene signature includes a
number of metabolic genes not previously linked to cancer. We
used siRNA inhibition to examine the role of 11 such metabolic
genes in cellular transformation. Efficient depletion of OLR1
(oxidized LDL receptor 1), GLRX, SNAP23, EGLN1, VAMP4,
GRN, and PGS1 (in most cases by two different siRNAs;
Figure S3) significantly reduced anchorage-independent growth
in soft agar in both epithelial and fibroblast transformation
models (Figure 4), but had no effect on growth of non-trans-
formed MCF10A cells (Figure S3C). Depletion of SCD1 reduced
colony formation in the fibroblast model, depletion of FGD6
reduced colony formation in the MCF10A epithelial model, and
depletion of MRLP9 and MOCOS had no effect. Thus, 9 out of
11 metabolic genes not previously linked to cancer tested arend gene sets of 32 diseases derived from literature (number of references indi-
the overlap with the cancer gene signature and the p value for the significance
lular transformation and the indicated diseases, with significant relationships
Cancer Cell 17, 348–361, April 13, 2010 ª2010 Elsevier Inc. 353
Figure 4. Metabolic GenesAffect the Tumorigenicity of Transformed
Cells
(A) Number of colonies in soft agar (mean ± SD) of untreated and TAM-treated
MCF10A ER-Src cells 24 hr posttransfection with siRNAs against the indicated
genes (NC indicates negative control siRNA). Number of colonies are pre-
sented as the mean ± SD of three experiments.
(B) Soft agar colony or foci assay in nontransformed (EH) and transformed
(ELR) BJ fibroblasts 24 hr posttransfection with siRNAs against the indicated
genes (mean ± SD).
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Cancer Gene Signature Is Linked to Other Diseasesimportant for cellular transformation, and 7 of these are involved
in both experimental models.
OLR1, SNAP23, VAMP4, and SCD1 are lipid-related genes,
and LDL is a common hub between cancer and metabolic
gene networks, suggesting the importance of lipid metabolism
during cellular transformation. Because OLR1 (oxidized LDL
receptor) expression is induced in a transformation-dependent
(Figure 5A) and depletion of OLR1 shows the strongest effects
on anchorage-independent growth in both models, we further
examined the role of OLR1 in the MCF-10A model. Depletion
of OLR1 by two different siRNAs blocks morphological transfor-
mation (Figure 5B) and it inhibits cell motility (migration, invasion,
and wound-healing assays; Figure 5C and Figure S4). In
addition, cell growth of transformed cells (treated with TAM for
48 hr) is blocked by inhibition of OLR1 expression via siRNAs
or monoclonal antibody (Figure 5D). Thus, OLR1 and lipid
metabolism are important for cellular transformation and mainte-
nance of the transformed state.
OLR1 Is Important for Maintaining the Transformed
State in Cell Lines of Diverse Developmental Origin
To generalize these results, we examined the role of OLR1 in
developmentally diverse normal and cancer cell lines. siRNA-
mediated inhibition of OLR1 expression does not affect the354 Cancer Cell 17, 348–361, April 13, 2010 ª2010 Elsevier Inc.growth of nontransformed breast (MCF10A and HME1) or pros-
tate (PWR-1E) cells. In contrast, inhibition of OLR1 suppresses
growth of MCF7 (breast cancer), HepG2 (hepatocellular carci-
noma), and HeLa (cervical cancer) cells (Figure 6A). In addition,
inhibition of OLR1 reduces tumorigenicity (Figure 6B) of all three
cancer cell lines. Thus, OLR1 is important for maintenance of the
transformed state in a variety of developmentally unrelated
cancer cell lines.
OLR1-Mediated Activation of Inflammatory
and Hypoxic Pathways through NF-kB
Is Important for Cellular Transformation
OLR1 is activated in response to oxidized LDL, angiotensin II,
TNF-a, and other stress stimuli (Mehta et al., 2003), and TNF-a
production is increased very early (1–4 hr) during ER-Src trans-
formation (Figure 7A). OLR1 is a marker of atherosclerosis, and
it activates inflammatory and hypoxia pathways in vascular
endothelial cells and macrophages. Similarly, genes involved in
inflammation (e.g., IL-1b, IL-6, and IL-8) and hypoxia (HIF1a,
VEGF, and CA9) are induced during the process of cellular
transformation in the MCF-10A model. In accord with these
observations, inhibition of OLR1 reduces the level of the inflam-
matory- and hypoxia-regulated genes (Figure 7B), and it also
reduces NF-kB activation (Figure 7C) through inhibition of IkBa
phosphorylation (Figure 7D). Furthermore, TNF-a inhibition
blocks the activation of HIF1a, VEGF, and CA9, the downstream
targets of OLR1 (Figure 7E). In addition, simvastatin, a lipid-
lowering drug that inhibits OLR1 expression in endothelial cells,
strongly inhibits cellular transformation (Figure 7F) in a manner
associated with inhibition of NF-kB activity, but it does not affect
growth of nontransformed MCF10A cells (data not shown).
Conversely, treatment of MCF-10A cells with a low dose of
oxidized LDL (oxLDL) induces cellular transformation and colony
formation (Figures 7G and 7H and Figure S5), with 40%–50%
transformation observed after 72 hr and 85% observed after
120 hr. Transformation mediated by oxLDL requires NF-kB,
because inhibition of NF-kB (BAY-117082 treatment) blocks
transformation (Figures 7G and 7H). Taken together, these
observations suggest that OLR1 regulates the inflammatory
and hypoxia responses during transformation in the MCF-10A
model and that TNF-a is a ligand for OLR1 activation.
OLR1 Is Important for Tumor Growth in Mice
When injected as xenografts into nude mice, transformed
MCF10A-ER-Src cells invariably cause tumors. Intraperitoneal
injection of siRNA against OLR1 (four cycles every 5 days) causes
a marked reduction in tumor growth (Figure 8A), and along with a
strong decrease in OLR1 expression levels (Figure 8B). In con-
trast, parallel injections of a control siRNA into the same cohort
of tumor-containing mice have no effect on tumor growth or
OLR1 expression. Thus, OLR1 is important for tumor growth in
mouse xenografts.
Lipid Metabolism Genes OLR1, GLRX, and SNAP23
Are Often Coordinately Overexpressed in Late-Stage
Breast and Prostate Cancer Tissues
We examined whether expression of OLR1, GLRX, and SNAP23
is altered in human cancers (Figures 8C and 8D). OLR1 is over-
expressed in 37% of mammary adenocarcinomas and 25% of
Figure 5. OLR1 Regulates Transformation,
Cell Growth, and Motility
(A) OLR1 mRNA expression levels (mean ± SD) in
untreated and TAM-treated MCF10A ER-Src cells
and the EH, EL, and ELR BJ fibroblasts.
(B) Representative phase-contrast images (scale
bars represent 25 mm) of MCF10A ER-Src cells
that were or were not treated with TAM together
with two different siRNAs against OLR1.
(C) Migration and invasion assays in untreated and
TAM-treated MCF10A ER-Src cells in the pres-
ence or absence of control or OLR1 siRNAs. For
all panels, the data are presented as mean ± SD.
(D) Cell growth of MCF10A ER-Src TAM-treated
cells (mean ± SD) after treatment with control or
OLR1 siRNAs or with an OLR1 antibody and an
IgG isotype control relative to untreated cells.
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pression is observed. GLRX and SNAP23 are overexpressed in
17% and 29% of mammary adenocarcinomas and in 14% and
16% of prostate adenocarcinomas, although the magnitude of
overexpression is less than observed for OLR1. When tumors
are classified according to clinicopathological parameters,
average mRNA expression levels of these genes increase with
the stage grading of the tumor, with stage IV tumors showing
high levels in most cases. In many, but not all, stage IV tumors,
these three lipid metabolism genes are overexpressed, sugges-
tive of coordinate regulation. Thus, lipid metabolism genes are
often overexpressed in breast and prostate cancer tissues,
and high levels of expression are associated with more aggres-
sive, metastatic stage tumors.
DISCUSSION
Identification of a Cancer Gene Signature
We define a cancer gene signature by a common set of genes
that are differentially regulated in the same manner in two diverse
models of cellular transformation. Several features of this
approach are advantageous. First, isogenic models make it
possible to identify genes involved in transformation without
the complications of unknown and irrelevant genetic differences
between non-transformed and transformed cells. Second, the
two diverse model systems help to distinguish transformation-
specific genes from genes that are regulated in a cell-type
specific manner. In this regard, our cancer gene signature
contains only 343 genes, whereas thousands of genes are differ-
entially regulated in only one experimental model. This increased
specificity is important for mechanistic understanding of
transformation and for increasing the statistical significance of
bioinformatics analyses. An important consequence of thisCancer Cell 17, 348–3specificity is our discovery of genes
involved in lipid metabolism as contrib-
uting to cellular transformation. Third,
the inducible Src system in MCF-10A
cells offers the unique opportunity to
kinetically follow the transcriptional
program of cellular transformation in
a manner similar to that used to studyviral infection and other temporally ordered processes. Impor-
tantly, the transcriptional signature derived from the combined
analysis of two isogenic, but biologically unrelated, models of
cellular transcription is highly correlated with a wide variety of
human cancers, thereby validating the clinical relevance of our
experimental models.
A Role For Lipid Metabolism in Cellular Transformation
and a Link between Cancer and Atherosclerosis
Although most genes in the cancer gene signature have been
previously linked to cancer by some criterion, some have not.
In support of their functional importance and relevance to
cancer, 7 out of 11 such genes tested are important for cellular
transformation in both experimental models (2 others in one
model) and those tested are overexpressed in breast and pros-
tate cancer tissues. Unexpectedly, genes involved in lipid
metabolism are highly enriched in our cancer gene signature,
particularly among those not previously linked to cancer. For
example, OLR1, SNAP23, VAMP4, SCD1, and SREBP1 are
lipid-related genes, and LDL is a common hub between cancer
and metabolic gene networks. Similarly, GALNT2 is associated
with high cholesterol and triglyceride levels (Kathiresan et al.,
2008), but not been linked with any type of cancer.
Strikingly, oxidized LDL can cause transformation of MCF-10A
cells lacking ER-Src in a manner that depends on NF-kB.
The receptor for oxidized LDL, OLR1, is a marker for atheroscle-
rosis, and it activates inflammatory and hypoxia pathways in
vascular endothelial cells and macrophages. In the MCF10A
ER-Src model, inhibition of OLR1 also reduces NF-kB activation
and the inflammatory and hypoxia pathways, suggesting a
mechanistic connection between cellular transformation and
atherosclerosis. Finally, OLR1 is important for maintaining the
transformed state in cancer cell lines of diverse developmental61, April 13, 2010 ª2010 Elsevier Inc. 355
Figure 6. OLR1 Regulates Cell Growth and
Tumorigenicity of Cancer Cells
(A) Cell growth of normal (MCF10A, HME1, PWR-
1E) and cancer (MCF7, HepG2, HeLa) cells after
treatment with control or OLR1 siRNAs. Data are
presented as mean ± SD.
(B) Soft agar colony assays for the cancer cell
lines. The data are presented as mean ± SD.
Cancer Cell
Cancer Gene Signature Is Linked to Other Diseasesorigin, and for tumor growth in xenografts experiments. Thus, the
importance of OLR1 and other genes involved in lipid metabo-
lism in cellular transformation is relevant for, and a major deter-
minant of, the connection between cancer and atherosclerosis.
The finding of lipid metabolism genes in our cancer gene signa-
ture is noteworthy, because breast epithelial cells and primary
fibroblasts are not major players in lipid biology and are function-
ally unrelated to cells involved in heart disease.
A Common Molecular Signature for Diverse
Human Diseases
Clinical and epidemiological studies have linked cancer with
inflammatory and metabolic diseases. In addition, specific
molecular pathways involved in cancer are also involved in
inflammatory diseases (e.g., NF-kB) and metabolic diseases
(e.g., Akt). Our cancer gene signature and underlying regulatory
networks significantly extend these observations by linking
cancer with a variety of human diseases in a genome-wide
manner that is based solely on experimental models of cellular
transformation. These links between cancer gene signature
and other diseases are robust, because they are based on (1)356 Cancer Cell 17, 348–361, April 13, 2010 ª2010 Elsevier Inc.common biological functions, (2) correla-
tions with literature-based annotations of
individual human diseases, (3) similarity
to transcriptional profiles of diseased
patients, and (4) identification and over-
lap of central nodes that define regulatory
pathways. Furthermore, it is striking the
studies of cellular transformation in
breast epithelial cells and fibroblasts
uncovered connections to diseases in-
volving developmentally unrelated cell
types and biological functions.
More importantly, our results indicate
that many disease states share common
molecular properties and biological
programs. These similarities go beyond
pairwise connections between cancer
and a particular disease or regulatory
pathway. Further, they do not simply
reflect a stress response, because the
transcriptional signature is not linked to
any stress conditions. Instead, our results
strongly argue that a core group of bio-
logical pathways is critical for normal
cellular growth and behavior in a variety
of cell types. Genetic or physiological
disruption of these pathways leads to a
transcriptional signature that is commonto a diverse set of human diseases. As a consequence, genetic
or environmental factors that affect the common genes or gene
networks should predispose individuals to the development of
multiple human diseases, and may contribute to the epidemio-
logical connections between seemingly unrelated pathologic
conditions. However, our results do not address whether the
presence of one disease per se, increases the probability that
another disease state may arise, because the different disease
states involve different cell types and hence may arise indepen-
dently. Conversely, the existence of a common transcriptional
program and regulatory network for many diseases suggests
that drugs used to treat one disease may be effective against
other diseases. In this regard, 11 out of 13 drugs used to treat
non-cancer diseases inhibit cellular transformation.
How does a common transcriptional program contribute to a
diverse set of human diseases? We suggest that the interplay
between cell-type specific transcription factors and the
common transcriptional program leads to cell-type specific
transcription profiles and phenotypes that are associated
with specific disease states. This suggestion is in accord with,
and indeed prompted by, the well-established principle that
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Cancer Gene Signature Is Linked to Other Diseasesexpression of mammalian genes requires combinations of tran-
scriptional regulatory proteins bound to enhancers (Struhl,
1991). In this view, the combination of cell-type specific factors
with a common disease program can either lead to inappro-
priate proliferation diagnostic of cancer or nonproliferative
abnormalities that lead to other diseases such as diabetes or
atherosclerosis.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions
MCF-10A ER-Src and MCF-10A pBABE cells were grown in DMEM/F12
medium supplemented as described in Debnath et al. (2003) with the addition
of puromycin. The Src oncogene was induced by the addition of 1 mM tamox-
ifen (Sigma) to confluent cell cultures for times indicated in the text. For testing
the effect of drugs on transformation, each drug was titrated for optimum inhi-
bition with minimal effects on nontransformed cells. All BJ fibroblast cell lines,
described previously (Hahn et al., 1999), were cultured on KO-DMEM media,
10% FBS, Medium 199 glutamine, and Pen/strep. Each drug used in the
drug screen was titrated for optimum inhibition with minimal effects on
nontransformed cells. The following drugs were used in the following concen-
trations: metformin (0.1 mM), cerulenin (1 mg/ml), tocilizumab (2 mg/ml), aspirin
(0.1 mM), exendin4 (15 mm), sulindac (100 mM), simvastatin (10 mM), meloxi-
cam (30 mM), indomethacin (30 mg/ml), celecoxib (10 mM), piroxicam
(100 mM), nimesulide (50 mM), sulindac (100 mM), mevastatin (1 mM).
RNA Preparation
RNA was extracted from all cell lines by Trizol method followed by RNeasy
columns purification. These samples were hybridized on an Affymetrix U133
2.0A array at the Dana Farber Array Facility.
Gene Expression Analyses
All gene expression data were normalized and summarized with RMA
algorithm (Irizarry et al., 2003) with an updated Entrez gene probeset definition
(Dai et al., 2005). ComBat (Johnson et al., 2007) was used to remove nonbio-
logical experimental variation or batch effects between batches of microarray
experiments. In order to detect differentially expressed genes, significance
analysis of microarrays (SAM) algorithm (Tusher et al., 2001) was used to
calculate the q-values (false discovery rate) for genes in each time point. For
ER-Src expression arrays, seven samples were used as controls, including:
Er-src_12EtOH (D1, D2, D3), Er-src_24EtOH (D1, D3), Er-src_0hr_TAM
(D2, D3). A gene will be regarded as differentially expressed gene, only if (1)
it was ‘‘present,’’ in terms Affymetrix MAS5 present/absent calls, in at least
one time point, and (2) q value < 1 (either upregulated or downregulated) in
at least one time point.
Disease Gene Sets
Gene sets were collected directly from previously published papers. These
include the 1406 gene set for metabolic disorders (Chen et al., 2008), the
494 gene set for atherosclerosis (Sluimer et al., 2007), the 60 gene set for
inflammatory breast cancer (Lerebours et al., 2008), the 28 gene set for inflam-
matory gastric cancer (Ellmark et al., 2006), the 687 gene set for thyroid cancer
(Delys et al., 2007), and the 80 gene set for pancreatic cancer (Logsdon et al.,
2003).
Lever Algorithm Analysis
The Lever algorithm was described previously (Warner et al., 2008). We incor-
porated the phylogenetic information from 12 mammals (mouse, rat, human,
rabbit, chimp, macaque, cow, dog, armadillo, tenrec, opossum, and elephant)
and used the MultiZ 17-way alignment as described in Supplemental Experi-
mental Procedures. The PBM data used in the study were for 104 TFs (tran-
scription factors) from 22 structural classes (Badis et al., 2009) and for 178
TFs from the Homeodomain class (Berger et al., 2008). We used ‘‘Seed-and-
Wobble’’ algorithm that has been described previously (Berger et al., 2006)
in order to represent these data as position weight matrices (PWMs) for
each TF. We used these PWMs in the Lever analysis.Ingenuity Pathway Analysis
Ingenuity pathways analysis (Ingenuity Systems, Mountain View, CA) is a
robust and expertly curated database containing up-to-date information on
over 20,000 mammalian genes and proteins, 1.4 million biological interactions,
and 100 canonical pathways incorporating over 6,000 discreet gene concepts.
This information is integrated with other relevant databases such as Entrez-
Gene and Gene Ontology. The experimental data sets were used to query
the IPA and to compose a set of interactive networks taking into consideration
canonical pathways, the relevant biological interactions, and the cellular and
disease processes.
Statistics
The overlap count was computed by counting the number of genes in the inter-
section between two different gene sets. P values were calculated by Fisher
exact test and hypergeometric probability distribution analysis in order to
estimate the statistical significance of overlap between two gene sets.
Small Interference RNA Transfection Experiments
MCF10A ER-Src cells were seeded in 6-well plates and were transfected with
100 nM siRNAs from Ambion Inc. against OLR1 (s9842 and s9843), GLRX
(s5841 and s229668), PLAU (s10610 and s10612), GRN (s6149 and s6151),
PGS1 (s18191 and s18192), SCD1 (s12505), FGD6 (s31504), MRPL9
(s35151), MOCOS (s230170), MYC (s1930), AKT (s659), SOCS3 (s17190),
STAT3 (s744), HIF1A (s6539), NF-kB (s11914), IL6 (s7313), RAS (s806),
VEGF (s460) using siPORT NeoFX transfection agent. SiPORT NeoFX is a lipid
transfection agent consisting of a mixture of lipids that spontaneously complex
small interference RNA and facilitates its transfer to the cells. Transfection with
100 nM siRNA (s4390846) was used as a control. No cell toxicity was detected
due to the transfection agent.
Soft Agar Colony Assay
Triplicate samples were mixed 4:1 (v/v) with 2.0% agarose in cell growth
medium for a final concentration of 0.4% agarose. The cell mixture was plated
on top of a solidified layer of 0.5% agarose in growth medium. Cells were fed
every 6 to 7 days with growth medium containing 0.4% agarose. The number
of colonies was counted after 15 days. The experiment was repeated thrice
and the statistical significance was calculated using Student’s t test.
Cell Migration, Invasion, and Wound-Healing Assays
For the migration assay, 105 trypsinized cells were added to the top chambers
of the transwell (8 mm pore size; BD Bioscience, Bedford, MA), and assay
medium was added to the bottom chambers. After overnight incubation,
the migratory cells were fixed and stained with 0.1% crystal violet solution.
The experiment was repeated thrice and the statistical significance was calcu-
lated with a Student’s t test. Invasion of matrigel has conducted by using
standardized conditions with BDBioCoat growth factor reduced MATRIGEL
invasion chambers (PharMingen). Assays were conducted according to the
manufacturer’s protocol, with 5% horse serum (GIBCO) and 20 ng/ml EGF
as chemoattractants. Wound-healing assays have been described previously
(Hirsch et al., 2009).
RNA Analysis
Equal amounts of purified RNA samples from untreated and TAM-induced
(1, 2, 4, 8, 12, 16, 24, and 36 hr) MCF10A ER-Src cells or from other cancer
cell lines were reverse-transcribed to form cDNA, which was subjected to
SYBR Green based real-time polymerase chain reaction analysis. For analysis
of patient samples, RNAs from 48 mammary adenocarcinoma tissues and
3 normal mammary tissues and from 44 prostate adenocarcinoma and
3 normal tissues were purchased from Origene (Rockville, MD). The experi-
ments have been performed in triplicate and data are presented as mean
and standard deviation (SD).
ELISA Assays
The NF-kB/p65 ActivELISA Kit measured nuclear p65 levels in MCF10 ER-Src
untreated or TAM-treated for 36 hr. The anti-p65 antibody coated plate
captures free p65 and the amount of bound p65 is detected by adding a
second anti-p65 antibody followed by alkaline phosphatase (AKP) -conjugated
secondary antibody using colorimetric detection in an enzyme-linkedCancer Cell 17, 348–361, April 13, 2010 ª2010 Elsevier Inc. 357
Figure 7. OLR1 Regulates Transformation through NF-kB Pathway
(A) TNF-a levels (mean ± SD) at the indicated time points during transformation.
(B) VEGF, HIF1A, and CA9 mRNA levels (mean ± SD) assessed in nontreated (NT) and TAM-treated (36 hr) MCF10A ER-Src cells in the presence or absence of
two different siRNAs against OLR1.
(C) NF-kB activity (ELISA assay; mean ± SD) in untreated and TAM-treated MCF10A ER-Src cells in the presence of the indicated siRNAs or 10 mM simvastatin.
(D) IkBa phosphorylation levels (ELISA assay; mean ± SD) in untreated and TAM-treated MCF10A ER-Src cells in the presence or absence of control or OLR1
siRNAs.
(E) VEGF, HIF1A, and CA9 mRNA levels (mean ± SD) assessed in Ab-IgG or Ab-TNFa treated ER-Src cells.
(F) Representative phase contrast images (scale bars represent 10 mm) of untreated and TAM-treated MCF10A ER-Src cells in the presence or absence of
simvastatin.
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Figure 8. OLR1 Is Important for Tumor Growth and Overexpressed Along with GLRX and SNAP23 in Cancer Tissues
(A) Tumor volume (mean ± SD) of mice injected at time 0 with transformed MCF10A-ER-Src cells that were untreated, or treated by intraperitoneal injections every
5 days (four cycles starting at day 15; arrows indicate the day or injections) with 100 nM siRNA against OLR11 or an siRNA control.
(B) OLR1 expression levels (mean ± SD) from tumors derived from the above experiment.
(C) Expression of OLR1, GLRX, and SNAP23 in breast cancer tissues separated by clinicopathological stage.
(D) Expression of OLR1, GLRX, and SNAP23 in prostate cancer tissues separated by clinicopathological stage.
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Cancer Gene Signature Is Linked to Other Diseasesimmunosorbent assay (ELISA) plate reader at absorbance 405 nm. To detect
IkBa phosphorylation status (serine 32), we used a solid phase sandwich
ELISA (cat no 7276, Cell Signaling) according to the manufacturer’s instruc-
tions. The magnitude of the absorbance (450 nm) is proportional to the quantity
of bound target protein. To detect TNF-a production, we used a TNF-alpha
Quantikine ELISA Kit (cat no. DTA00C, R&D Systems) according to the
manufacturer’s instructions. For all ELISA assays, each sample was loaded
in triplicate and data are presented as mean ± SD.(G) Representative phase-contrast images (scale bars represent 10 mm) and (H)
presence or absence of 5uM NF-kB inhibitor (BAY-117082). For all relevant paneTumor Growth in Xenografts
For assessing the role of OLR1, 5 3 106 transformed MCF10A ER-Src cells
were injected into the right flank of 15 female nu/nu mice (Charles River
Laboratories), all of which developed tumors in 15 days with size 125 mm3.
The mice were randomly distributed into three groups that were untreated,
or treated by intraperitoneal injections every 5 days (four cycles) with 100 nM
siRNA against OLR1 or a control siRNA. To assess the effects of metformin
(20 mg/kg), cerulenin (40 mg/kb), simvastatin (20 mg/kg), and sulindacnumber of colonies of MCF10A cells treated with oxidized LDL (oxLDL) in the
ls, the data are presented as mean ± SD.
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Cancer Gene Signature Is Linked to Other Diseases(15 mg/kg), the same procedure was followed except that drug treatment
started 10 days of tumor formation (size 60 mm3). Tumor volume was
measured at various times after the initial injection. All mouse experiments
were approved by the Tufts University Institutional Animal Care and Use
Committee.
ACCESSION NUMBERS
Microarray data have been deposited at GEO with the accession number
GSE17941.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and nine tables and can be
found with this article online at doi:10.1016/j.ccr.2010.01.022.
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